Opko健康 OPK 深 沪
等待开盘 11-03 09:30:00 美东时间
1.36
-0.100
-6.85%
华盛通- 最 高1.44
- 今 开1.42
- 成交量 397.84万股
- 最 低 1.35
- 昨 收 1.46
- 总市值 10.80亿
- 52周最高 2.035
- 市盈率 静 --
- 换手率 0.50%
- 52周最低 1.11
- 委 比 -83.83%
- 总股本 7.94亿
- 历史最高 19.20
- 量 比 2.32
- 振 幅 6.16%
- 历史最低 0.8516
- 每 手 1
- 风险率 0.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
今天 10:30
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
10-31 10:25
Earnings Scheduled For October 29, 2025
Companies Reporting Before The Bell • OppFi (NYSE:OPFI) is expected to report q...
10-29 19:11
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
<p>ModeX Therapeutics and Regeneron Pharmaceuticals have entered into a collaboration to develop multispecific antibodies targeting multiple disease pathways. ModeX will receive USD $7 million upfront, plus potential milestone and royalty payments exceeding USD $200 million per molecule, with a potential total value over $1 billion. The MSTAR platform will be used to create innovative antibody candidates for indications like immunology, oncology,...
10-29 12:00
OPKO Health Q3 Earnings Preview
OPKO Health (NASDAQ:OPK) is scheduled to announce Q3 earnings results on Wednesday, October 29th, after market close. The consensus EPS Estimate is -$0.04 and the consensus revenue estimate is $165.74...
10-29 05:35
An OPKO Health's Modex Therapeutics Company Doses First Patient In Its Phase 1/2a Trial Of MDX2004, A First-In-Class Trispecific Antibody-fusion Protein For Advanced Cancers
First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 ModeX Therapeutics
10-28 20:08
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers
A Phase 1/2a clinical trial has begun with MDX2004, a novel trispecific antibody-fusion protein targeting CD3, CD28, and 4-1BB to enhance T cell activation for advanced cancers. This drug aims to rejuvenate cellular immunity by expanding stem and memory T cell populations, offering potential for diverse cancers and immune impairments. Two abstracts on MDX2004 will be presented at the 2025 SITC Annual Meeting. ModeX Therapeutics, an OPKO Health co...
10-28 12:00
Opko Health Sells BioReference Assets to Labcorp
Opko Health ( ($OPK) ) just unveiled an update. On September 15, 2025, OPKO Hea...
09-16 04:38
Entera Bio Presents Preclinical Data For OPK-8801003, Oral GLP-2 Tablet With Longer Half-Life Aiming To Replace Daily Injections For Short Bowel Syndrome Patients
Preclinical Data for OPK-8801003 Demonstrate Substantially Longer Biological Half-Life with Peak Plasma Levels Comparable to Gattex®, the Only Approved GLP-2 TherapyOral GLP-2 Tablet Could Transform Treatment
09-15 21:05
Opko Health shares are trading lower after the company reported worse-than-expected Q2 sales results.
Opko Health shares are trading lower after the company reported worse-than-expe...
08-02 00:48
